Coherus BioSciences, Inc. financial data

Symbol
CHRS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
C/O Dennis M. Lanfear, 333 Twin Dolphin Dr, Suite 600, Redwood City, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
BioGenerics, Inc. (to 1/3/2012)
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 151 % -45.5%
Quick Ratio 20 % -22.4%
Debt-to-equity -519 % +3.22%
Return On Assets -9.69 % +82.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 115 M shares +42.4%
Common Stock, Shares, Outstanding 113 M shares +41%
Entity Public Float 324 M USD -26.9%
Common Stock, Value, Issued 11 K USD +37.5%
Weighted Average Number of Shares Outstanding, Basic 113 M shares +42.2%
Weighted Average Number of Shares Outstanding, Diluted 126 M shares +58.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 104 M USD -31.1%
Costs and Expenses 480 M USD +12.4%
Operating Income (Loss) -178 M USD +27%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -59.7 M USD +78%
Income Tax Expense (Benefit) -380 K USD
Net Income (Loss) Attributable to Parent -59.3 M USD +78.2%
Earnings Per Share, Basic -0.66 USD/shares +81%
Earnings Per Share, Diluted -0.74 USD/shares +78.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 260 M USD +1509%
Marketable Securities, Current 14.9 M USD -88.4%
Inventory, Net 62 M USD +25.4%
Assets, Current 627 M USD +98.6%
Property, Plant and Equipment, Net 4.19 M USD -45.8%
Operating Lease, Right-of-Use Asset 5.91 M USD +3.9%
Intangible Assets, Net (Excluding Goodwill) 71.7 M USD +1108%
Goodwill 943 K USD 0%
Other Assets, Noncurrent 9.13 M USD +16.7%
Assets 764 M USD +89.7%
Accounts Payable, Current 38.3 M USD +64.8%
Employee-related Liabilities, Current 22.8 M USD +83.2%
Accrued Liabilities, Current 116 M USD +261%
Liabilities, Current 538 M USD +336%
Deferred Income Tax Liabilities, Net 1.1 M USD
Operating Lease, Liability, Noncurrent 4.98 M USD +37.2%
Other Liabilities, Noncurrent 2.73 M USD +2580%
Liabilities 845 M USD +41.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -272 K USD +2.16%
Retained Earnings (Accumulated Deficit) -1.48 B USD -4.18%
Stockholders' Equity Attributable to Parent -81.8 M USD +58.4%
Liabilities and Equity 764 M USD +89.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -46.8 M USD +32%
Net Cash Provided by (Used in) Financing Activities 887 K USD -76.7%
Net Cash Provided by (Used in) Investing Activities 203 M USD +1057%
Common Stock, Shares Authorized 300 M shares 0%
Common Stock, Shares, Issued 113 M shares +41%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 157 M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 260 M USD +1469%
Deferred Tax Assets, Valuation Allowance 423 M USD +25.3%
Deferred Tax Assets, Gross 430 M USD +26.4%
Operating Lease, Liability 6.4 M USD -5.24%
Payments to Acquire Property, Plant, and Equipment 152 K USD -75.3%
Lessee, Operating Lease, Liability, to be Paid 7.94 M USD +7.32%
Operating Lease, Liability, Current 1.42 M USD -54.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.19 M USD -27.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.1 M USD -41.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure +50%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.54 M USD +138%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.13 M USD +416%
Deferred Tax Assets, Operating Loss Carryforwards 170 M USD +29.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5 M shares
Unrecognized Tax Benefits 17.4 M USD +3.44%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.53 M USD +424%
Additional Paid in Capital 1.4 B USD +14.2%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.9 M USD -33.3%
Share-based Payment Arrangement, Expense 7.32 M USD -40.4%
Interest Expense 41.9 M USD +26.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares